← Back
Data updated: Jul 17, 2026
ISO TEX
Biotech Pharmaceuticals
ISO TEX is a biotechnology company with 4 FDA-approved products.
1940
Since
4
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Biologics
ISO TEX's Key Drugs
ISO TEX's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
No active drugs
ISO TEX's Recent FDA Approvals
New NDA/BLA approvals for ISO TEX over the last two years — novel drugs only, excluding generics and label supplements.
No recent approvals
ISO TEX's Therapeutic Areas
Disease areas where ISO TEX has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
No indication data
ISO TEX Pipeline Snapshot
Active clinical trials for ISO TEX across all therapeutic areas, from ClinicalTrials.gov.
No active pipeline data available
Pro Expected Approvals & Milestones
Loading detailed analysis...
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Unlock Full Intelligence
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 1940-04-30
- Latest
- 2023-08-25
- Applications
- 4